>Rabbit PAb Antibody
>CHI3L1 / YKL40 Antibody (Antigen Affinity Purified)
|Catalog||Size (Price)||Quantity||In Stock||Operation||Other Information|
CHI3L1 / YKL40 Antibody ( Antigen Affinity Purified ) Datasheet
|Order or Inquire for CHI3L1 / YKL40 Antibody product||Quality antibodies||Antibody production services|
|Detection limit is 0.5 ng/lane in WB|
|Detection limit is 0.00975 ng/well in ELISA|
CHI3L1 / YKL40 Antibody Product Information
Recombinant Human CHI3L1 / YKL40 protein (Catalog#11227-H08H)
|Antibody Type :||Rabbit Polyclonal Antibody ( Antibody Purification Platform )|
|Ig Type :||
|Formulation :||0.2 μm filtered solution in PBS with 5% trehalose|
Produced in rabbits immunized with purified, recombinant Human CHI3L1 / YKL40 (rh CHI3L1 / YKL40; Catalog#11227-H08H; NP_001267.2; Met 1-Thr 383). CHI3L1 / YKL40 specific IgG was purified by Human CHI3L1 / YKL40 affinity chromatography.
CHI3L1 / YKL40 Antibody Usage Guide
Human CHI3L1 / YKL40
|Western blot :||This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human CHI3L1 in WB. Using a DAB detection system, the detection limit for Human CHI3L1 is approximately 0.5 ng/lane under non-reducing conditions and reducing conditions.|
|Direct ELISA :||This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human CHI3L1. The detection limit for Human CHI3L1 is approximately 0.00975 ng/well.|
|Storage :||This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
CHI3L1 / YKL40 Antibody Related Products & Topics
|Molecule||Species||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|CHI3L1/YKL40||Human||CHI3L1/YKL40 Protein, Recombinant||11227-H08H|
|CHI3L1/YKL40||Mouse||CHI3L1 / gp39 Protein, Recombinant||50929-M08H|
|Molecule||Application||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|Human CHI3L1/YKL40||WB, ELISA||CHI3L1 / YKL40 Antibody||11227-RP01|
|Human CHI3L1/YKL40||WB, ELISA||CHI3L1 / YKL40 Antibody (Antigen Affinity Purified)||11227-RP02|
|Human CHI3L1/YKL40||IHC-P||CHI3L1 / YKL40 Antibody||11227-MM04|
CHI3L1 / YKL40 Antibody Background
Chitinase-3-like protein 1, also known as Cartilage glycoprotein 39, and CHI3L1, is a member of the glycosyl hydrolase 18 family. The principal sources of CHI3L1 are activated macrophages and chondrocytes, neutrophils, and some tissue and tumor cells. CHI3L1 is a secreted glycoprotein that is upregulated in a number of human cancers and in non-neoplastic disease states characterized by chronic inflammation and tissue remodeling. Increased serum levels of CHI3L1 parallel disease severity, poorer prognosis, and shorter survival in many human neoplasias, including cancers of the breast, colon, prostate, ovaries, brain, thyroid, lung, and liver. Increased serum CHI3L1 also correlates with disease severity in rheumatoid arthritis, osteoarthritis, liver fibrosis, inflammatory bowel disease, and bacterial septicemia. CHI3L1 can act as a fibroblast mitogen and can activate several signaling pathways. Elevated levels of CHI3L1 are associated with disorders exhibiting increased connective tissue turnover, such as rheumatoid arthritis, osteoarthritis, scleroderma, and cirrhosis of the liver. The ability of CHI3L1 to bind both proteins and carbohydrates allows potential interactions with a variety of cell-surface and extracellular-matrix proteins, proteoglycans, and polysaccharides, and thus CHI3L1 can interface between proteomics and glycomics. CHI3L1 may play an important role in the capacity of cells to respond to and cope with changes in their environment.
- Nishikawa, KC. et al., 2003,Exp Cell Res. 287 (1): 79-87.
- Rehli, M.et al., 2003, J Biol Chem. 278 (45): 44058-67.
- Recklies, AD. et al., 2005, J Biol Chem. 280 (50): 41213-21.
- Coffman, FD. 2008, Crit Rev Clin Lab Sci. 45 (6): 531-62.